Naga Anvesh Kodali

Dr. Naga Anvesh Kodali

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SPSupriya Peshin
Supriya Peshin
ETEhab Ayman Takrori
Ehab Ayman Takrori
NKNaga Anvesh Kodali
Naga Anvesh Kodali
FBFaizan Bashir
Faizan Bashir
SSSakshi Singal
Sakshi Singal
Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy with rising incidence and dismal long-term survival, largely due to late-stage presentation and intrinsic resistance to therapy. Recent advances in the multidisciplinary management of PDAC have reshaped treatment paradigms across disease stages. For localized disease, innovations in surgical techniques and the adoption of neoadjuvant strategies have improved resection rates and survival outcomes. In metastatic settings, multiagent chemotherapy regimens and precision therapies targeting BRCA mutations and rare gene fusions are expanding treatment options. Immunotherapeutic modalities, including checkpoint inhibitors, adoptive cell therapies, and mRNA vaccines, show emerging promise despite PDAC’s traditionally immunosuppressive microenvironment. This review synthesizes the current evidence on established therapies and critically evaluates novel and investigational approaches poised to redefine the therapeutic landscape of pancreatic cancer.

11 July 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
SPSupriya Peshin
Supriya Peshin
FBFaizan Bashir
Faizan Bashir
NKNaga Anvesh Kodali
Naga Anvesh Kodali
ADAdit Dharia
Adit Dharia
SZSajida Zaiter
Sajida Zaiter
NMNagaishwarya Moka
Nagaishwarya Moka
Immunotherapy has emerged as a transformative approach in gastrointestinal (GI) cancers, addressing historically poor survival rates in advanced-stage disease. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis demonstrate remarkable efficacy in colorectal cancer with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H), exemplified by trials like NICHE-2 achieving exceptional pathological response rates. However, significant limitations persist, including resistance in some dMMR/MSI-H tumors, minimal efficacy in proficient mismatch repair (pMMR) tumors, and low overall response rates across most GI malignancies due to tumor heterogeneity and immune evasion mechanisms. Predictive biomarkers such as tumor mutational burden (TMB) and PD-L1 expression are crucial for optimizing patient selection, while hypermutated pMMR tumors with POLE mutations represent emerging therapeutic opportunities. In pancreatic adenocarcinoma, where survival remains dismal, combination strategies with chemotherapy and novel approaches like cancer vaccines show promise but lack transformative breakthroughs. Esophagogastric cancers benefit from ICIs combined with chemotherapy, particularly in MSI-H and HER2-positive tumors, while hepatocellular carcinoma has achieved significant progress with combinations like atezolizumab–bevacizumab and durvalumab–tremelimumab surpassing traditional therapies. Biliary tract cancers show modest improvements with durvalumab–chemotherapy combinations. Despite these advances, immunotherapy faces substantial challenges including immune-related adverse events, acquired resistance through cancer immunoediting, and the need for biomarker-driven approaches to overcome tumor microenvironment barriers. This review discusses key clinical trials, therapeutic progress, and emerging modalities including CAR T-cell therapies and combination strategies, emphasizing the critical need to address resistance mechanisms and refine precision medicine approaches to fully realize immunotherapy’s potential in GI malignancies.

Verified
Journal Article
Open access
PDF file
SPSupriya Peshin
Supriya Peshin
ETEhab Ayman Takrori
Ehab Ayman Takrori
NKNaga Anvesh Kodali
Naga Anvesh Kodali
FBFaizan Bashir
Faizan Bashir
Michael K GibsonMichael K Gibson
Michael K Gibson
SSSakshi Singal
Sakshi Singal
Gastroesophageal cancer (GEC) represents a global health burden, with rising incidence and high mortality. Despite advancements in early detection and systemic therapies, outcomes remain poor, especially in advanced stages. Management requires a multidisciplinary, multimodal approach that integrates surgery, chemotherapy, radiotherapy, targeted agents, and immunotherapy, tailored by tumor histology, location, and molecular profile. For localized disease, perioperative chemotherapy or chemoradiotherapy is standard, with adjuvant immunotherapy now emerging in selected high-risk cases. In metastatic or unresectable settings, systemic therapy forms the backbone of treatment, with biomarker-driven regimens targeting HER2, PD-L1, MSI-H/dMMR, and CLDN18.2, offering improved outcomes. Novel agents and combinations, including bispecific antibodies, FGFR2 inhibitors, and immunotherapy-based strategies, are actively being explored in clinical trials. This review provides a comprehensive overview of the evolving therapeutic landscape of GEC. It emphasizes the growing role of precision medicine and the integration of emerging clinical data into practice.

28 November 2024 in JPRAS Open
Verified
Journal Article
Open access
Yalcin KulahciYalcin Kulahci
Yalcin Kulahci
NKNaga Anvesh Kodali
Naga Anvesh Kodali
ZDZeynep Demir
Zeynep Demir
ODOmer Dirican
Omer Dirican
BSBedreddin Sazoglu
Bedreddin Sazoglu
VGVijay S. Gorantla
Vijay S. Gorantla

13 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
FBFaizan Bashir
Faizan Bashir
SPSupriya Peshin
Supriya Peshin
MRMoniza Rafiq
Moniza Rafiq
SZSajida Zaiter
Sajida Zaiter
NKNaga Anvesh Kodali
Naga Anvesh Kodali
SSSakshi Singal
Sakshi Singal
Background : Metabolic syndrome (MetS) is a significant global health burden and a known risk factor of cardiovascular disease and diabetes. Growing evidence also links MetS to cancer development, likely via chronic inflammation, insulin resistance, and hormone disruption. However, its association with laryngeal cancer remains largely unclear and underexplored. Methods: For this review, we thoroughly searched PubMed/MEDLINE, Scopus, and Web of Science for observational studies investigating associations of MetS with laryngeal or head and neck cancers (HNCs) until 1 August 2025. Five large population-based studies were found to meet inclusion criteria, and risk of bias was assessed using the Joanna Briggs Institute checklist (JBI). Results: Three Korean cohort studies consistently found that MetS increased the risk of laryngeal cancer (HR 1.13–1.32), independent of smoking and alcohol use. Hypertension and hyperglycemia were the most consistent components associated with increased risk, and chronic MetS conferred the highest hazard. In contrast, analyses from the UK Biobank (HNC) and SEER-Medicare (HNSCC) cohorts showed null and inverse associations, respectively. Additional findings included dose–response effects with increasing MetS components, U-shaped associations for HDL-C and waist circumference and increased risk associated with elevated C-reactive protein. Conclusions: Current evidence suggests a possible association between MetS and risk of laryngeal cancer, although the direction and strength of effect vary across populations. Findings from Korean cohorts provide consistent signals of increased risk, whereas Western datasets have not replicated this pattern. Overall, the certainty of evidence is low to moderate, warranting cautious interpretation and further validation in diverse populations before inferring causality.

26 March 2026 in Clinical Transplantation and Research
Verified
Journal Article
Open access
PDF file
BSBedreddin Sazoglu
Bedreddin Sazoglu
ODOmer Dirican
Omer Dirican
ZDZeynep Demir
Zeynep Demir
NKNaga Anvesh Kodali
Naga Anvesh Kodali
FDFatma Esra Demir
Fatma Esra Demir
Vijay Saradhi GorantlaVijay Saradhi Gorantla
Vijay Saradhi Gorantla
Bedreddin Sazoglu, Omer Dirican, Zeynep Demir, Naga Anvesh Kodali, Fatma Esra Demir, Ramu Janarthanan, Fatih Zor, Yalcin Kulahci, Vijay S. Gorantla. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0079